197 related articles for article (PubMed ID: 33935035)
1. The clinical role of interferon alpha in Philadelphia-negative myeloproliferative neoplasms.
Yoon SY; Won JH
Blood Res; 2021 Apr; 56(S1):S44-S50. PubMed ID: 33935035
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms.
Huang CE; Wu YY; Hsu CC; Chen YJ; Tsou HY; Li CP; Lai YH; Lu CH; Chen PT; Chen CC
J Formos Med Assoc; 2021 Feb; 120(2):863-873. PubMed ID: 32873465
[TBL] [Abstract][Full Text] [Related]
3. Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure?
Hasselbalch HC; Holmström MO
Semin Immunopathol; 2019 Jan; 41(1):5-19. PubMed ID: 30203226
[TBL] [Abstract][Full Text] [Related]
4. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.
Krecak I; Skelin M; Verstovsek S
Expert Rev Hematol; 2023 May; 16(5):305-316. PubMed ID: 37002907
[TBL] [Abstract][Full Text] [Related]
5. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
6. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
Zeuzem S; Sulkowski MS; Lawitz EJ; Rustgi VK; Rodriguez-Torres M; Bacon BR; Grigorescu M; Tice AD; Lurie Y; Cianciara J; Muir AJ; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG;
Gastroenterology; 2010 Oct; 139(4):1257-66. PubMed ID: 20600013
[TBL] [Abstract][Full Text] [Related]
7. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
[TBL] [Abstract][Full Text] [Related]
8. HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?
Vlachogiannakos J; Papatheodoridis GV
Liver Int; 2014 Feb; 34 Suppl 1():127-32. PubMed ID: 24373089
[TBL] [Abstract][Full Text] [Related]
9. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture.
Liu C; Zhu H; Subramanian GM; Moore PA; Xu Y; Nelson DR
Hepatol Res; 2007 Nov; 37(11):941-7. PubMed ID: 17573950
[TBL] [Abstract][Full Text] [Related]
10. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L; Bose P; Verstovsek S
Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
12. An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Infect Chemother; 2012 Oct; 18(5):689-97. PubMed ID: 22450877
[TBL] [Abstract][Full Text] [Related]
13. [Interferon in hepatitis B].
García Buey L; González Mateos F; Moreno Otero R
Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
[TBL] [Abstract][Full Text] [Related]
14. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner SM; Melchardt T; Greil R
Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.
Villa E; Cammà C; Di Leo A; Karampatou A; Enea M; Gitto S; Bernabucci V; Losi L; De Maria N; Lei B; Ferrari A; Vukotic R; Vignoli P; Rendina M; Francavilla A
J Viral Hepat; 2012 Sep; 19(9):640-9. PubMed ID: 22863268
[TBL] [Abstract][Full Text] [Related]
16. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia.
Lipton JH; Khoroshko N; Golenkov A; Abdulkadyrov K; Nair K; Raghunadharao D; Brummendorf T; Yoo K; Bergstrom B;
Leuk Lymphoma; 2007 Mar; 48(3):497-505. PubMed ID: 17454589
[TBL] [Abstract][Full Text] [Related]
17. Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study.
Barbaro G; Grisorio B; Fruttaldo L; Bacca D; Babudieri S; Torre D; Francavilla R; Rizzo G; Belloni G; Lucchini A; Annese M; Matarazzo F; Hazra C; Barbarini G
BioDrugs; 2003; 17(6):433-9. PubMed ID: 14614766
[TBL] [Abstract][Full Text] [Related]
18. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a signaling feedback circuit that defines interferon responses in myeloproliferative neoplasms.
Saleiro D; Wen JQ; Kosciuczuk EM; Eckerdt F; Beauchamp EM; Oku CV; Blyth GT; Fischietti M; Ilut L; Colamonici M; Palivos W; Atsaves PA; Tan D; Kocherginsky M; Weinberg RS; Fish EN; Crispino JD; Hoffman R; Platanias LC
Nat Commun; 2022 Apr; 13(1):1750. PubMed ID: 35365653
[TBL] [Abstract][Full Text] [Related]
20. Potential of interferon-alpha in solid tumours: part 1.
Decatris M; Santhanam S; O'Byrne K
BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
